Alteogen signs option and license pact with Novartis for Hybrozyme-enabled products
Alteogen entered an option and license agreement with Novartis covering development and commercialization of Hybrozyme™-enabled subcutaneous products.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.